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bioprosthesis: Durability results up to 21 years
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Christine Detschades, SRN, Henryk Siniawski, MD, PhD, and Roland Hetzer, MD, PhD
Objective: The study aim was to analyze the performance profile of a large series of
Mitroflow pericardial valves (Sorin Group Canada Inc. Mitroflow Division) in the
very long term.
Methods: Data from 1513 patients with isolated aortic valve replacement who re-
ceived pericardial bioprostheses between 1986 and 2007 were analyzed. Cumulative
duration of follow-up was 6164 patient-years with a maximum duration of 21 years.
Actuarial rates of valve-related events were calculated by the Kaplan–Meier method
and the Cox multivariate analysis to identify independent determinants of outcome.
Results: Hospital mortality for elective surgery was 2.5%. Late death was 40.6%. Re-
operation was required in 86 (5.7%) patients and was valve related in 83: structural
valve deterioration in 64 (4.2%) patients, prosthetic valve endocarditis in 17 patients
(1.1%), valve thrombosis in 1, and periprosthetic leak in 1. Rates of 20-year actuarial
freedom from valve-related morbidity were as follows: structural valve deterioration
84.8% (actual 96.6%) in patients 70 years of age or older; thromboembolism 94.1%;
and prosthetic valve endocarditis 96.8%. Twenty-year actual risk of reoperation for
structural valve deterioration was 11.4% in all patients and 3.4%, in patients 70 years
or age or older. Advanced age, renal insufficiency, pulmonary disease, and low body
mass index were independent risk factors for late outcome (P , .001).
Conclusions:After 2 decades of follow-up, theMitroflow pericardial aortic valve con-
tinues to be a valve of choice with a predictable low rate of valve-related events, par-
ticularly for patients over the age of 65 to 70 years and others with comorbidities.
A
lthough the pericardial bioprosthesis was once unpopular for clinical use be-
cause of design-related early structural deterioration,1-3 it has demonstrated
its potential for midterm and long-term durability beyond 15 years.4-11 It is
now apparent that durability and performance resulting from improved design of sec-
ond-generation pericardial tissue valves are even better when the valves are implanted
in a selected group of patients.6-11 The Mitroflow pericardial bioprosthesis (Sorin
Group Canada Inc. Mitroflow Division) has demonstrated excellent hemodynamics,
comparable with stentless porcine valves and superior to similar stented bioprosthe-
ses,8,12-20 especially in small sizes. The very long-term durability is not yet estab-
lished. For this reason, we evaluated clinical data from 1513 patients who received
single Mitroflow pericardial aortic valve replacement from March 1986 to determine
the long-term clinical durability and threshold age for implantation.
Patients and Methods
Over a period of 21 years betweenMarch 1986 and December 2007, 1760Mitroflow pericardial
bioprostheses were implanted in 1722 consecutive patients in the aortic, mitral, tricuspid, and
pulmonary positions as single, double, or triple procedures. A total of 1513 patients received
single aortic valve replacements. There were 1071 (70.8%) women and 442 (29.2%) men. Pre-
operative characteristics of the study population are shown in Table 1.
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CDAbbreviations and Acronyms
NYHA 5 New York Heart Association
CI 5 confidence interval
CL 5 confidence limits
OR 5 odds ratio
PVE 5 prosthetic valve endocarditis
SVD 5 structural valve deterioration
TE 5 thromboembolism
The results of 17-year durability on 1037 patients in the series
have been reported8; the follow-up is now extended to 21 years.
Four hundred seventy-six additional patients who were operated
on in the interim have been followed up to 2.69 years for 482.06 pa-
tient-years (mean: 1.017 6 0.35 SEM) with the previous series.
Surgical Technique
Standard surgical procedures were performed as described previ-
ously.8 Themajor aspects of implantation are as follows:Meticulous
decalcification is used to avoid abrasion and early alteration to the
pericardial valve by residual calcific tissue. The decalcified annulus
allows proper matching and secures good coaptation of leaflets.
A sizing obturator is used to measure the native annulus for
proper selection of the pericardial valve size, using clinical judg-
ment of the space in the supra-annular area of the aortic sinuses.
This will avoid oversizing, which creates valve deformation. In sit-
uations in which subaortic obstructive septal hypertrophy is present,
incision or preferably resection (myectomy) should be performed.
Enlargement of a small aortic annulus is rare, but if it is necessary
the Nicks procedure can be performed to avoid squeezing and defor-
mation of the valve.
Despite the valve’s low-profile characteristics, proper orientation
of the anatomic units of the pericardial prosthesis should be ob-
served.
The valve should be inserted in a supra-annular position to avoid
hemodynamic stress, and the valve commissures should correspond
to native commissures while the valve sinuses face the coronary os-
tia to achieve unobstructed coronary ostia. Finally, very tall knots
that would expose valve tissue to abrasion, early alteration, and per-
foration should be avoided.
Data Collection and Postoperative Follow-up
The study, as well as the use of patients’ data for research purposes
and publication, was approved by the institutional review board and
informed consent was obtained from the follow-up patients.
Data acquisition. Patients were examined at our institution or
have been contacted by telephone interview and mailed question-
naire. Further patient data were obtained from hospital records, fam-
ily physicians, and cardiologists. Patients with unknown addresses
could be tracked through the district or state registry of residents
or birth and deaths.
Total follow-up was 6163.5 patient-years (mean: 4.07 6 0.12
years, SEM). Eleven (0.7%) patients were lost to follow-up
(99.3% complete). A total of 1297 (85.7%) of the hospital survivors
underwent routine echocardiographic studies at 3 and 9 months after
operation and thereafter annually. Transthoracic Doppler echocardi-The Journal of Thoography was performed at different institutions in a uniform manner
and the evaluations were comparable. If a patient had undergone
more than one echocardiographic or clinical evaluation, the result
of the most recent investigation was reported.
We evaluated 189 measurements of mean gradients in 121 pa-
tients. Measurement of mean gradients and time intervals between
TABLE 1. Characteristics of patients
No. of patients 1513
Mean age (y) 73.2 6 0.22 (SEM)
Range (y) 22–95
Female 1071 (70.8%)
Male 442 (29.2%)
Distribution of
patients by age group
Age (y) n %
,60 89 5.8
60-69 366 24.2
70-79 722 47.7
$65 1324 87.5
$70 1058 69.9
$80 336 22.2
NYHA
II 620 (41%)
III 633 (41.8%)
IV 210 (13.9)
Unknown 50 (3.3%)
Body mass index
Mean (kg/m2) 25.74 6 0.12 (SEM)
Range kg/m2 12.98–47.5
Renal failure 159 (10.5%)
Pulmonary disease (COPD) 152 (10%)
Carotid stenosis 104 (6.9%)
Aortic valve pathomorphology
Aortic stenosis 707 (46.7%)
Aortic incompetence 278 (18.4%)
Mixed lesion 487 (32.2%)
Prosthesis dysfunction 41 (2.7%)
Etiology N
Degenerative 1217
Congenital 13
Acute/subacute endocarditis 40
Healed endocarditis 202
Prosthesis dysfunction 41
CABG procedure 759 (50.2%)
Implanted
valve size
(N 5 1513)
Explanted
valve size
(N 5 86)
19 mm 204 (13.5%) 10 (0.7%)
21 mm 869 (57.4%) 35 (2.3%)
23 mm 347 (22.9%) 30 (2.0%)
25 mm 76 (5.0%) 6 (0.4%)
27 mm 17 (1.1%) 1 (0.06%)
Unknown 4 (0.3%)
NYHA, New York Heart Association; COPD, chronic obstructive pulmonary
disease; CABG, coronary artery bypass grafting; SEM, standard error of
the mean.racic and Cardiovascular Surgery c Volume 136, Number 3 689
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Therefore, we did not apply the mixed model longitudinal regres-
sion analysis as described by Banbury and associates.4 We are pre-
senting scatterplots of mean gradients of valve sizes 19 to 25 mm
and their median values to demonstrate the evolution of transvalvu-
lar mean gradients across time.
Structural and nonstructural valve deterioration of Mitroflow bi-
oprostheses, diagnosed preoperatively by echocardiographic stud-
ies, was confirmed at the time of explantation.
At the time of the last follow-up study, 150 patients (29%) were
in New York Heart Association (NYHA) class I, 232 (45%) in class
II, 120 (23%) in class III, and 14 (3%) patients could not be classi-
fied because of advanced age.
Ninety-seven (7.6%) patients were receiving anticoagulation
treatment with warfarin sodium (Coumadin) and 260 (20.5%)
with antiplatelet drugs. Three hundred fifteen (24.8%) patients 65
years of age or older were receiving anticoagulants as compared
with 42 (3.3%) patients younger than 65 years.
NYHA functional classification of the patients was inconsistent
and unreliable to reproduce owing to a high proportion of patients at
advanced age (mean age at operation 73 years). Many follow-up pa-
tients discontinued or irregularly took their drugs partly because of
the risk and fear of bleeding and stroke. Therefore, a statistical ap-
proach to estimate a time-related proportion of patients in NYHA
functional class and receiving anticoagulants did not yield meaning-
ful, reproducible clinical information.
Statistics. The probability of survival, freedom from valve-re-
lated morbidity events, death, and reoperation were estimated by
Kaplan–Meier actuarial analysis and by linearized occurrence rates.
Linearized occurence rates of events and confidence limits were cal-
culated according to Poisson distribution.
Actual competing risk analysis (cumulative incidence) was
performed.
Tabular data are summarized by the mean and given with stan-
dard error for continuous variables and by percentages for categor-
ical variables. Differences in actuarial freedom between groups of
patients are determined by the log–rank test. Differences in prognos-
tic variables between two groups were evaluated by t tests for con-
tinuous variables and the c2 or Fisher exact test for categorical
variables. Predictors of events during follow-up were identified by
the Cox proportional hazards regression.
All variables listed in Table 1 were investigated for association
with hospital death, overall death, and valve-related complications
by univariate and multivariate analysis. Standard statistical formulas
have been used for the analysis of data, as described previously.8
Results
Patient Survival
Hospital survival. Thirty-day hospital survival was
97.5% for elective patients and 90.2% for patients in
NYHA functional class III–IV (odds ratio [OR], 3.9; confi-
dence interval [CI] (95% confidence limits [CL]) 1.31–
12.07; P value .015).
The causes of early death were cardiac related in 96 (61%)
patients and noncardiac and nonvalve related in 61 (39%) pa-
tients. Significant predictive factors for early mortality were
emergency operation (OR, 1.53; CI [95% CL] 1.33–1.75;690 The Journal of Thoracic and Cardiovascular Surgery c SepP value , .001) and preoperative renal failure (OR, 2.76;
CI [95% CL] 0.98–7.76; P value .054).
Long-term survival. A total of 615 patients died. Twenty-
five (4.1%) deaths were valve related. Actuarial freedom
from valve-related death at 20 years was 82.9% 6 4.0%.
The actuarial survival including operative death in our co-
hort at 10, 15, and 20 years was 31.9% 6 1.8%, 12.7% 6
1.4%, and 6.1% 6 1.5%, respectively (Figure 1; OR, 1.82;
CI [95% CL] 1.55–2.18; P value , .001). Univariate and
multivariate analysis showed that NYHA III–IV (OR, 1.37;
CI [95% CL] 1.18–1.59; P value, .001), renal insufficiency
(OR, 1.74; CI [95% CL] 1.40–2.17; P value, .001), chronic
obstructive pulmonary disease (OR, 1.54; CI [95%CL] 1.22–
1.95; P value .001), body mass index less than 20 kg/m2 (OR,
1.46; CI [95% CL] 1.13–1.88; P value .001), and advanced
age (OR, 1.82; CI, 1.56–2.16; P value , .001) were predic-
tive factors for late death.
On the other hand, small valve size (19 mm: OR, 1.09; CI,
0.86–1.38; P value 0.458; 21 mm: OR, 1.68; CI, 0.65–4.38:
1.38; P value .286) and gender (OR, 1.11; CI, 0.96–1.29;
P value .158) were not independent risk factors.
Of 435 follow-up patients, after 1 year 136 were in NYHA
class I, 202 in class II, 87 in class III, and 10 in class IV; after
5 years, of 45 patients 6 were in class I, 19 in class II, 18 in
class III, and 2 in class IV; after 10 years, of 36 patients 8
were in class I, 11 in class II, 15 in class III, and 2 in class
Figure 1. Overall cumulative survival of all 1513 patients after aor-
tic valve replacement and of a German population as background
(data from Federal Bureau for Population Statistics, Wiesbaden,
Germany).tember 2008
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class II, 3 were in class III, and 1 in class IV. Anticoagulation
was administered in all patients for 6 weeks after discharge.
After 1 year 138 of 995 follow-up patients were receiving an-
ticoagulants, after 5 years 116 of 493, after 10 years 52 of
156, and after 15 years 51 of 58 follow-up patients were
receiving anticoagulants.
Valve-related Complications
Reoperation. Reoperation was required in 86 patients and
was valve related in 83. Causes were as follows: structural
valve deterioration (SVD) in 64 (4.2%) cases, valve thrombo-
sis in 1 case (0.07%), periprosthetic leak in 1 case (0.07%),
and prosthetic valve endocarditis (PVE) in 17 (1.1%) cases.
The 20-year actual risk of reoperation for all causes was
15.5% with a linearized rate of 1.4%/pt-y (CI, 1.05–1.62).
SVD. Sixty-four (4.2%) patients had primary tissue failure
resulting from leaflet calcification or fibrosis causing stenosis
in 8, incompetence in 30 (including 1 leaflet tear inMitroflow
early experience), or mixed lesion in 26 patients. Detailed
analysis is shown in Table 2. Overall 20-year freedom from
SVDwas 62.31 5.02%. Actuarial freedom from reoperation
for SVD at 20 years in patients aged 65 years or older and 70
years or older was 71.8% 6 6.0% (actual, 92.66 4.6%) and
84.8 6 0.7% (actual, 96.6% 6 0.8%), respectively (Figures
2–4 and Table 3). The 20-year actual risk (cumulative inci-
dence) for SVD was 11.4%. The linearized rate of SVD for
the entire patient cohort was 0.9%/pt-y. It was 0.76%/pt-y
and 0.34%/pt-y for patients aged 65 years or older and 70
years or older, respectively. Younger patients, below the
age of 65 years, had a linearized rate for SVD of 2.1%/pt-y
(P5 .004). Detailed linearized rates of events and confidence
limits at different age groups are shown in Table 3.
The leaflet disruption observed in 1 patient occurred at the
base of the commissural site facing the noncoronary aortic
annulus (linearized rate, 0.016%/pt-y; CI, 0.0004–0.08).
Time-related transvalvular mean gradients and valve
size. Repeated measurements of transvalvular mean gradi-
ents and valve sizes across time are shown in Table 4 and Fig-
ure 5. Postoperative transvalvular mean gradient with valve
TABLE 2. Summary of causes for reoperation and
explantation of 86 Mitroflow valves
Causes n
SVD 63
Leaflet tear 1
PVE* 17
Periprosthetic leak 1
Valve thrombosis 1
Technical 2
Intraop. mismatch 1
SVD, Structural valve deterioration; PVE, prosthetic valve endocarditis.
*Perivalvular abscess 5 1; leaflet tear 5 1.The Journal of Thosize 19 mm was greater than that with 21 mm and 23 mm;
however, all were decreased at 1 year.
In patients aged 65 years or more, mean transvalvular gra-
dient at 5 years for valve sizes 19 to 25 mm was 12 to 6 mm
Hg. This increased to 18 to 8 mm Hg after 10 years and then
remained stable at 15 and 20 years for valve sizes 21 and 23
mm, respectively (Figure 5).
In contrast, patients less than 65 years showed a significant
increase in transvalvular mean gradient to 40 to 19 mm Hg or
more after 10 years for valve sizes 21 and 23 mm (P5.004),
leading to reoperation (Figure 2).
Nonstructural valve dysfunction. There was 1 (0.07%)
case of nonstructural valve dysfunction: periprosthetic leak
(0.07%). An additional 3 dysfunctions were not valve related:
2 technically related (0.13%) and 1 intraoperative mismatch
(0.07%) (Table 2).
Thromboembolism. Forty-nine (3.2%) patients had epi-
sodes of thromboembolsm (TE) representing an actuarial
freedom of 94.1% at 20 years (Figure 6). The linearized
rate was 0.79%/pt-y.(CI, 0.60–1.01). TE occurred in 6
(0.4%) patients under 65 years of age (linearized rate,
0.5%/pt-y; CI, 0.24–1.06) and in 43 (2.8%) patients 65 years
of age or older (linearized rate, 0.93%/pt-y; CI, 0.66–1.18). In
the 49 patients with stroke, 4 neurologic events were perma-
nent (linearized rate, 0.06%/pt-yr) and 9 (linearized rate,
0.09%/pt-yr; CI, 0.07–0.25) were fatal. TE was recurrent in
Figure 2. Actuarial freedom from reoperation for structural valve
deterioration (SVD) in age groups (50–59, 60–69, and $70 years)
after pericardial aortic valve replacement.racic and Cardiovascular Surgery c Volume 136, Number 3 691
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Age Patients at risk
Years 1 5 10 15 20 Linearized rate
%/pt, yr
CL
50–59 58 36 14 4 — 1.9 1.78–14.78
60–69 269 156 61 17 — 2.0 1.33–2.67
$65 853 401 100 20 1 0.76 0.6–1.3
$70 658 291 61 9 1 0.4 0.22–0.73nine patients. One patient experienced a valve thrombosis
(linearized rate: 0.02%/pt-y).
Bleeding. There were 4 nonfatal cases of hemorrhagic
events under anticoagulation therapy (linearized rate,
0.065%/pt-y; CI, 0.02–0.15) The indication for anticoagula-
tion was atrial fibrillation or cardiologic decision. None of the
patients experienced a recurrent bleeding episode.
PVE. Seventeen (1.1%) patients with a sterile aortic root
at primary operation had a prosthetic infection. The organ-
isms associated with late infections were staphylococcal
and streptococcal species. Among the 202 patients with
healed endocarditis and 40 with active endocarditis, there
was 1 episode of reinfection in each group. Significant para-
valvular leaks resulting from infection were observed in 5
patients (linearized rate, 0.08%/pt-y; CI, 0.03–0.17) and
a leaflet tear in 1 of the patients.
Figure 3. Actual (cumulative incidence) freedom from reoperation
for structural valve deterioration (SVD) by age group (50–59, 60–69
and $70 years) after pericardial aortic valve replacement.692 The Journal of Thoracic and Cardiovascular Surgery c SepThe actuarial freedom from endocarditis was 96.8% 6
0.9% at 20 years and the linearized rate for endocarditis
was 0.28%/pt-y (CI, 0.14–0.44, Figure 7). There were con-
stant very low hazard events of PVE.
Discussion
Our current series of 1513Mitroflow stented low-profile peri-
cardial bioprostheses represents one of the largest single in-
stitutional experience with the longest follow-up (21 years).
For xenograft tissue valves, the porcine bioprosthesis is
taken as the standard against which results can be compared.
The potential for a very long-term durability of stented peri-
cardial and stented porcine tissue valves for over 20 years has
been demonstrated and reported recently.8,21,22
Statistical comparison between actuarial data reported
from various institutions is very difficult, but literature re-
view can help to gain a general impression.5,8,17,18,20,23-25
Figure 4. Actuarial and actual (cumulative incidence) freedom
from reoperation for structural valve deterioration (SVD) in age
group $65 years after pericardial aortic valve replacement.tember 2008
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structures treated with glutaraldehyde, their shape, technique
of mounting, mode of function, and fluidodynamic character-
istics are dissimilar and therefore their long-term perfor-
mance and mode of failure may be different.
Twenty-one–year durability of the Mitroflow pericardial
bioprosthesis attests to the quality of the pericardial tissue
and the design/shape of this bioprosthesis. In comparison
with porcine valves, the Mitroflow pericardial valve is less
obstructive especially in the 19- and 21-mm sizes and even
competes well with porcine stentless valves.8,14-20 Sustained
long-term durability over 21 years has been demonstrated in
patients older than 70 years with 84.8% (actual, 96.6%) free
of SVD.
The 72% 21-year actuarial (actual, 92.6%) freedom from
SVD in patients over 65 years with Mitroflow pericardial tis-
sue valves compares favorably with Hancock II (Medtronic,
Inc, Minneapolis, Minn) porcine valves (actuarial freedom
from SVD of 73%.) in patients in similar age groups.21 Other
reports also confirmed that the pericardial valve is as durable
as porcine and allograft valves at ages above 65 years.24
Several authors have reported leaflet tears and early SVD
even in elderly patients, which was a rare event in our se-
ries.1-3,5,21,26 The etiology of early SVD associated with leaf-
let tears in a subgroup of elderly patients is not clearly
understood.
In our series, leaflet tears or disruptions occurred in 2
patients. Leaflet tear as a primary tissue failure occurred in 1
patient, which represents a linearized rate of 0.02%/pt-y
(CI, 0.0004–0.08), whereas the other leaflet tear was associ-
ated with PVE. This indicates that if there is a history of endo-
carditis, aswe encountered in our patient, the tear is secondary
to the infection and the complication has to be classified as
endocarditis and excluded from the SVD group, as reported
in the guidelines of Edmunds and associates27 and by other
authors.21,29,30 Acceleration of structural deterioration could
occur after a successful treatment of endocarditis.7,28 It is
therefore important to consider the history of previous antibi-
otic treatment and exclude endocarditis as an underlying
cause before classifying a tear as a primary tissue failure.
The analysis of our 21-year results withMitroflow pericar-
dial bioprostheses in the aortic position has shown it to be
TABLE 4. Postoperative echocardiographic data and
labeled prosthesis size in 121 patients
Mean gradient (mm Hg)
Prosthesis size (mm) n Range Median
19 18 7–19 10.5
21 83 6–50 11.5
23 9 5–40 9
25 11 5–12 8The Journal of Thosafe even at withdrawal of anticoagulation or antiplatelet
treatment in 92% and 80% of the patients, respectively.
The risk of late TE complications impact with an incidence
of 3.8% and a linearized rate of 0.79%/pt-y (CI, 0.60–1.01).
The major indication for long-term anticoagulation was
atrial fibrillation. Valve thrombosis and lethal TE were en-
countered in 1 (0.02%/pt-y) and another 9 (0.7%pt-y) patients
in this series, respectively, and the potential hazard of antico-
agulant-induced hemorrhage was significantly low (n 5 4,
0.3%) with a linearized rate of 0.06%/pt-y (CI, 0.02–0.15).
The incidence of 3.4% TE complications in patients
older than 65 years of age could be explained by the
fact that the average patient age in the series was over
73 years and the risk of cerebral accidents developing
from unrecognized cerebrovascular lesions without cardiac
surgery was already high.26 The disparity in TE rates be-
tween our series and recently published data with porcine
valves is evident.5,18,21–23,25 The lower propensity for TE
in our cohort with the Mitroflow pericardial valve relates
to the quality of the tissue and the design of the prosthesis.
Although the exact etiology of early TE is not widely es-
tablished, our experience has indicated that many patients
could benefit from anticoagulant treatment for the initial
6 weeks after bioprosthetic aortic valve replacement. In
the presence of one or more factors associated with an in-
creased risk of TE (atrial fibrillation, enlarged left atrium
with or without thrombus, recurrent atrial fibrillation after
ablation), such patients with tissue valves should receive
lifelong anticoagulant therapy.
Figure 5. Time-related transvalvular mean gradients in relation to
labeled valve sizes. Each symbol represents a labeled valve size.
Solid lines represent time-related estimates of median values for
each prosthesis.racic and Cardiovascular Surgery c Volume 136, Number 3 693
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not found to be a risk factor for operative death. The low pa-
tient survival of 6% at 21 years with a median probability of
survival time of 6.8 years is attributed to the average patient
age of 73 years at implantation in our series, and it is in line
with the results obtained from meta-analysis of life expec-
tancy, which was 10.7 years for a 65-year-old patient after
aortic valve replacement.29
Furthermore, after 15 years the Kaplan–Meier estimates
for patient survival are not as reliable as the initial estimates
because of the limited number of patients at risk beyond 15
years. This translates in the mean follow-up per patient,
which is 4.07 years per patient in the present study and
4.85 years per patient in the 2003 study.8
Actuarial freedom from valve-related death in our series
was 94% at 10 years and 83% at 20 years. The result is in
line with data published by others.4,17,19 Although autopsies
were not performed in some patients who died with known
causes, they were performed in cases of unexplained or
sudden death with some exceptions (religious or cultural).
Figures on SVD were obtained at reoperation or autopsy.27
The available autopsy results did not show any acute SVD
or leaflet rupture as a cause of death. The long-term patient
mortality was caused much more commonly by patient-re-
lated factors than by the presence of theMitroflow pericardial
valve prosthesis, as described in the paragraph on long-term
survival of this article. Valve-related death of 4.1% (25/615)
was therefore low in our series and was overestimated as sud-
Figure 6. Actuarial freedom from thromboembolism (TE) after peri-
cardial aortic valve replacement.694 The Journal of Thoracic and Cardiovascular Surgery c Sepden or unexplained patient death and was the most common
cause of valve-related death. There was no direct correlation
between valve size and early or late death in patients with
19- to 21-mm and 23- to 25-mm Mitroflow bioprostheses
(P 5 .458 and P 5 .286). Further analysis to correlate with
NYHA functional class revealed even better results for
smaller valve sizes 19 to 21 mm (P 5 .003, P 5 .034).
Inasmuch as the physical capacity of elderly patients may
diminish over time, we did not use change in NYHA class as
a function for SVD or patient–prosthesis mismatch in these
patients without echocardiographic evidence. The analysis
has ruled out hemodynamically relevant patient–prosthesis
mismatch and testifies to the excellent hemodynamic perfor-
mance of small sizes of Mitroflow bioprostheses (mean trans-
valvular gradient [mm Hg]/effective orifice area [cm2] of 9.4
mm Hg/1.4 cm2, 7.1 mm Hg/1.6 cm2, and 4.7 mm Hg/1.85
cm2 for valve sizes 19 mm, 21 mm, and 23 mm, respectively)
as compared with other bioprostheses.4,8,12-20
Repeated measurements of transvalvular mean gradients
in relation to Mitroflow pericardial valve size across time
in patients aged 65 years or older showed that mean trans-
valvular gradient at 5 years for valve sizes 19 to 23 mm
was 12 to 5 mm Hg. This increased to 18 to 8 mm Hg after
10 years and then remained stable at 15 and 20 years for valve
sizes 21 and 23 mm, respectively.
In contrast, patients younger than 65 years showed an in-
crease in transvalvular mean gradient to 40 to 19 mmHg after
Figure 7. Hazard function of prosthetic valve endocarditis after
pericardial aortic valve replacement. Constant hazard rate of
events.tember 2008
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tion.
Patient–prosthesis mismatch was rare in our series,
however, 2 patients with 19-mm and 21-mm valves in the
supra-annular position were identified with a classic
prosthesis–patient mismatch (effective orifice area, 0.8 cm2/
m2), which could have been avoided by myectomy and the
Nicks procedure for enlargement of the noncoronary sinus,
respectively.
Frater,17 Banbury,4 and their associates reported mean
gradients of 22 to 15 mm Hg and 22 to 12 mm Hg for Car-
pentier–Edwards Perimount pericardial valve (Edwards Life-
sciences, Irvine, Calif) sizes 19 to 25 mm at 12 and 17 years
in patients at a mean age of 65 years, respectively. The gra-
dients reported were somewhat greater than those we found
in our cohort at 15 and 20 years. SVD observed in the first
5 years (n 5 7; linearized rate, 0.4%/pt-y; CI, 0.18–0.87) in
our cohort was confounded by sequelae of radiotherapy for
cancer, implantation technical reasons including a rare pa-
tient–prosthesis mismatch, and subclinical endocarditis,
whereas SVD beyond the 5-year period in the first decade
was associated with age below 65 years.1,5,7,20,21
PVE was a rare event that occurred in 17 (1.1%) patients,
and the rate of recurrent infection was 0.8% (n5 2). The ac-
tuarial freedom from PVE was 96.8% 6 0.0.9% and the lin-
earized rate was 0.28%/pt-y (CI, 0.14–0.44). The hazard rate
for PVE was constantly very low.20
Our results suggest that the freedom from valve-related
SVD, as well as the freedom from reoperation, and the TE
rate are all very competitive with results published for other
bioprostheses.17,18,21-25 The freedom from SVD and reoper-
ation are age related, as is the case in other reports of series
with bioprostheses.17,18,21,24 These data support our pro-
posals that the Mitroflow prosthesis is the valve of choice
in patients over the age of 65 to 70 years and a logical and
safe choice for patients younger than 65 years of age with
comorbidities.
Conclusions
The Mitroflow pericardial bioprosthesis exhibits very low
pressure gradients combined with easy implantability. After
2 decades of follow-up, theMitroflow pericardial aortic valve
continues to be a valve of choice with a predictable low rate
of valve-related events, particularly for patients over the age
of 65 to 70 years and others with comorbidities.
We are grateful to Anne M. Gale, ELS, for editorial assistance,
Astrid Benhennour for bibliographic support, and Carla Weber for
providing the graphics.
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